로딩 중…
지수 로딩 중…
이글벳
044960· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩3,055+2.52%
2026-08-04
Financials
Valuation Metrics
이글벳's Market Cap is ₩386B. At end of 2025 it was ₩529B. Ranked #1887 of 2,436 in KR market (top 77%), #1168 of 1,649 on KOSDAQ (top 71%), #206 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 88%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 38.62B KRW | KR#1,887/2,436 Sec#206/234 |
| Revenue | 43.61B KRW | KR#1,847/2,436 Sec#129/234 |
| Net Income | 4.33B KRW | KR#1,170/2,436 Sec#78/234 |
| Total Assets | 65.33B KRW | KR#2,027/2,436 Sec#172/234 |
| Net Assets | 52.38B KRW | KR#1,843/2,436 Sec#157/234 |
| Employees | 110 | KR#1,562/2,436 Sec#121/234 |
| Value | ||
| P/E | 8.91x | KR#642/2,436 Sec#32/234 |
| P/B | 0.74x | KR#1,224/2,436 Sec#68/234 |
| PEG | 0.24x | KR#563/2,436 Sec#33/234 |
| P/S | 0.89x | KR#1,335/2,436 Sec#76/234 |
| EV/EBITDA | 9.65x | KR#594/2,436 Sec#26/234 |
| Profitability | ||
| ROE | 8.28% | KR#668/2,436 Sec#42/234 |
| ROA | 6.63% | KR#462/2,436 Sec#34/234 |
| Op. Margin | 10.00% | KR#493/2,436 Sec#47/234 |
| Revenue Growth | 2.68% | KR#1,284/2,436 Sec#118/234 |
| Earnings Growth | 36.69% | KR#644/2,436 Sec#39/234 |
| Financial Health | ||
| Debt Ratio | 124.72% | KR#757/2,436 Sec#90/234 |
| Total Debt | 8.49B KRW | KR#1,671/2,436 Sec#153/234 |
| Cash | 5.05B KRW | KR#1,981/2,436 Sec#180/234 |
| Current Ratio | 3.41x | KR#531/2,436 Sec#79/234 |
| Net Debt/EBITDA | 0.79x | KR#780/2,436 Sec#52/234 |
| Dividend | ||
| Div. Yield | 2.69% | KR#731/2,436 Sec#40/234 |
| Div. Growth | 33.33% | KR#315/2,436 Sec#16/234 |
| Performance | ||
| 1Y Return | -29.28% | KR#1,470/2,436 Sec#123/234 |
| 1M Return | -2.86% | KR#470/2,436 Sec#32/234 |
| From 52W High | -36.88% | KR#599/2,436 Sec#38/234 |
| 1Y MDD | -38.56% | KR#471/2,436 Sec#35/234 |
| Trading | ||
| Volume | 42,348 shares | KR#1,951/2,436 Sec#191/234 |
| Foreign Own. | 1.58% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | 343 KRW | KR#1,062/2,436 Sec#74/234 |
| BPS | 4,267 KRW | KR#1,566/2,436 Sec#117/234 |
Company Info
Iglobet, established in 1983, manufactures, imports, and sells animal pharmaceuticals for major livestock species, while also developing new businesses in pet pharmaceuticals, feed, and accessories. The company, which was listed on KOSDAQ in 2000, obtained EU GMP certification for sterile injectable drugs in 2017, establishing a foothold for European exports. It employs a sales strategy that shares profits with distributors through its SD policy. Iglobet is headquartered in Yesan-gun, Chungcheongnam-do.